SMS Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 4/6
SMS Pharmaceuticals ha un patrimonio netto totale di ₹5.6B e un debito totale di ₹2.9B, che porta il suo rapporto debito/patrimonio netto a 50.6%. Le sue attività totali e le sue passività totali sono rispettivamente ₹11.3B e ₹5.7B. L'EBIT di SMS Pharmaceuticals è ₹955.7M rendendo il suo rapporto di copertura degli interessi 5. Ha liquidità e investimenti a breve termine pari a ₹90.7M.
Informazioni chiave
50.6%
Rapporto debito/patrimonio netto
₹2.85b
Debito
| Indice di copertura degli interessi | 5x |
| Contanti | ₹90.66m |
| Patrimonio netto | ₹5.64b |
| Totale passività | ₹5.71b |
| Totale attività | ₹11.35b |
Aggiornamenti recenti sulla salute finanziaria
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21
SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22Recent updates
Risks Still Elevated At These Prices As SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Shares Dive 25%
Nov 14SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( ₹5.8B ) di SMSPHARMA superano le sue passività a breve termine ( ₹3.8B ).
Passività a lungo termine: Le attività a breve termine di SMSPHARMA ( ₹5.8B ) superano le sue passività a lungo termine ( ₹2.0B ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: Il rapporto debito netto/patrimonio netto ( 49% ) di SMSPHARMA è considerato alto.
Riduzione del debito: Il rapporto debito/patrimonio netto di SMSPHARMA è aumentato da 43.2% a 50.6% negli ultimi 5 anni.
Copertura del debito: Il debito di SMSPHARMA è ben coperto dal flusso di cassa operativo ( 22.9% ).
Copertura degli interessi: I pagamenti degli interessi sul debito di SMSPHARMA sono ben coperti dall'EBIT ( 5 x copertura).